Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.44 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1671401 | 0.98 | ALDH1A1 (0.55) | ALDH1A1TP53TDP1KDM4EPOLB | |
| SCHEMBL11445345 | 0.85 | TAAR1 (0.58) | ALDH1A1TP53TDP1KDM4EPOLB | |
| SCHEMBL1293285 | 0.85 | TSHR (0.57) | ALDH1A1TP53KDM4EMAPTCDC25B | |
| SCHEMBL22627397 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTMRGPRX4LMNACSNK2A1 | |
| SCHEMBL16670730 | 0.83 | CSNK2A1 (0.45) | ALDH1A1KDM4ECSNK2A1KLKB1SMN1; SMN2 | |
| SCHEMBL13622158 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TP53TDP1KDM4EPOLB | |
| SCHEMBL6451619 | 0.82 | ALDH1A1 (0.52) | ALDH1A1TDP1KDM4EPOLBMAPT | |
| SCHEMBL844419 | 0.81 | CYP4F2 (0.61) | ALDH1A1TP53TDP1KDM4EPOLB | |
| SCHEMBL5113001 | 0.81 | FOLH1 (0.57) | ALDH1A1TP53TDP1KDM4EPOLB | |
| SCHEMBL30402090 | 0.81 | CYP4F2 (0.61) | ALDH1A1TP53TDP1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| CN-108997325-B | Aryl bithiazole compound and application thereof | 浙江工业大学 | 2020-08-04 | — | — | CN | disclosed |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-09-25 | — | — | US | disclosed |
| CN-105636951-B | Amide derivatives and its officinal salt, its preparation method and its application in medicine | 上海恒瑞医药有限公司 | 2018-05-15 | — | — | CN | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-8951999-B2 | Compounds | OREXO AB (SE) | 2015-02-10 | — | — | US | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-B1 | Inhibitors of the microsomal prostaglandin E2 synthase-1 | BOEHRINGER INGELHEIM INT (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2491007-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263556-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011048004-A1 | INHIBITORS OF THE MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-4182775-A | Benzoic acids and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263556-A1 | New Compounds | PTGES, PTGER1, PTGS1 | ALDH1A1 228/4885TP53 4149/4885TDP1 3133/4885 |
| US-10081629-B2 | Amide derivatives and pharmaceutically acceptable salts thereof, preparation method thereof and medicinal application thereof | PTGES, PTGS1, PTGIS | ALDH1A1 51/4885TP53 4153/4885TDP1 3280/4885 |
| US-20170037044-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND MEDICINAL APPLICATION THEREOF | PTGES, PTGS1, PTGIS | ALDH1A1 51/4885TP53 4153/4885TDP1 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.